TITLE

Financings Roundup

PUB. DATE
May 2008
SOURCE
BioWorld Today;5/15/2008, Vol. 19 Issue 95, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on a binding commitment entered by NexMed Inc. of East Windsor, New Jersey with one of its largest shareholders for a line of credit. The company intends to use the money to bridge the anticipated payments from partner Novartis AG, which licensed rights to NM100060 of NexMed. NM100060 is a topical treatment for onchomycosis.
ACCESSION #
32059915

 

Related Articles

  • Deals roundup.  // Medical Device Daily;7/9/2009, Vol. 13 Issue 130, p3 

    The article reports on the mutual decision of NexMed and Novartis to terminate their licensing agreement for NM100060, a topically-applied treatment for nail fungus. The licensing agreement was completed by the companies in September 2008. According to NexMed, the results of two Phase III...

  • NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product.  // Equities;Apr2007, Vol. 55 Issue 2, p124 

    The article reports on the start of patient dosing in the Phase 3 clinical trials for NM100060 anti-fungal treatment of Novartis according to NexMed Inc. which signed a licensing agreement with the pharmaceutical firm. It states that two pivotal, randomized, double-blind and placebo-controlled...

  • Infectious Diseases News Round-Up.  // PharmaWatch: Monthly Review;Aug2009, Vol. 8 Issue 8, p21 

    The article offers world news briefs related to the pharmaceutical industry. Baxter International Inc. is developing an A/H1N1 vaccine using its Vero cell culture technology to respond the outbreak of H1N1 influenza. Novartis AG has received requests from over 30 governments for the delivery of...

  • NexMed's U.S. patent triggers a milestone payment from Novartis.  // Medical Device Daily;10/29/2008, Vol. 12 Issue 211, p8 

    The article reports that the U.S. Patent & Trademark Office has issued a notice of allowance for NexMed's U.S. patent application titled, "Antifungal Nail Coat and Method of Use." The patent covers NM100060, a topical application of terbinafine formulated with NexACT for the treatment of...

  • NexMed Shares Fall Hard as Novartis Nixes NDA. Hollingsworth, Catherine // BioWorld Today;8/28/2008, Vol. 19 Issue 168, p1 

    The article reports on a decline in the value of NexMed's shares by 81.6% after its partner, Novartis AG, decided not to file for a new drug application for a topical nail fungus product that uses NexMed's drug delivery technology. Such decision by Novartis was attributed to a negative Phase III...

  • Tech startup of the month. Peterson, Eric // ColoradoBiz;May2002, Vol. 29 Issue 5, p49 

    Features the GlobeImmune Inc. in Denver, Colorado. Production of vaccine from brewer's yeast proteins; Focus on the HIV disease; Licensing agreement with Novartis.

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/7/2010, Vol. 21 Issue 108, p6 

    This section offers news briefs concerning the biotechnology industries, which include the licensing agreement between Ascalon International Inc. and CerRx Inc., the agreement between Emisphere Technologies Inc. and Novartis AG and preclinical data on the dual agonist of Toll-like Receptor 7...

  • Novartis in AMD deal.  // Optometry Today;5/23/2014, Vol. 54 Issue 10, p5 

    The article reports on a licensing agreement between pharmaceutical companies Novartis and Ophthotech concerning the non-U.S. commercial rights to Novartis' wet age-related macular degeneration (AMD) drug Fovista.

  • Agricultural biotechnology. Fairley, Peter // Chemical Week;7/22/1998, Vol. 160 Issue 27, p16 

    Reports on the expansion of the 1993 cross-licensing agreement between Novartis and Dow subsidiary Mycogen. Coverage of the licensing agreement; Products to be marketed by the companies; Comments from Michael Muston, president of Mycogen's seeds unit.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics